28 March 2024
HeiQ Plc
("HeiQ" or "the Company")
Unaudited Interim Results
HeiQ Plc (LSE: HEIQ), a leading company in materials innovation and hygiene technologies, announces its unaudited interim financial results for the 12 months ending 31 December 2023.
As announced on 14 March 2024, the Company has deemed it prudent to extend its accounting reference date to 30 June 2024. The next set of audited financial reports and accounts will therefore be for the period 1 January 2023 to 30 June 2024 and will be published by 31 October 2024, following the appointment of a new auditor.
Financial Overview:
· Revenue reduced 11.6% to US$41.7 million (12 months to 31 December 2022: US$47.2 million)
· Gross profit margin increased 8.5% to 37% (12 months to 31 December 2022: 28.5%)
· Adjusted LBITDA decreased to US$5.2 million (12 months to 31 December 2022: US$12.2 million)
· Operating loss of US$11.6 million (12 months to 31 December 2022: loss of US$29.2 million)
· Loss after taxation of US$14.0 million (12 months to 31 December 2022: loss of US$30.0 million)
· Cash at 31 December 2023 of US$9.7 million with net debt (including lease liabilities) of US$10 million
Operational Overview:
Challenging market conditions persisted during the period, leading to continued high inventories and weakened demand across the industry. HeiQ responded with decisive measures:
· New organizational structure established to drive growth and profitability of HeiQ's three venture initiatives (HeiQ AeoniQ, HeiQ GrapheneX and HeiQ ECOS).
· Strengthened financial reporting processes through the establishment of a central accounting function in Portugal.
· Advanced harmonizing the Enterprise Resource Planning (ERP) system across the group.
· Comprehensive actions taken to address deficiencies outlined by the former auditor.
Post Period:
· Julien Born appointed as CEO of HeiQ AeoniQ Holding to lead scale up.
· Robert van de Kerkhof appointed as new Chair of HeiQ plc, effective 1 April 2024.
· Successful fundraising of £2.4 million through placing, convertible loan note and retail offer.
· Acquisition of Portugal factory site for HeiQ AeoniQ's first commercial production plant.
Investor Presentation:
Carlo Centonze, CEO, and Xaver Hangartner, CFO, will provide a live presentation for investors via the Investor Meet Company platform at 11:00 am GMT today. The presentation is open to all existing and potential shareholders. Questions can be submitted at any time during the live presentation. Investors can sign up to Investor Meet Company for free and click "Add to Meet" HEIQ PLC via:
https://www.investormeetcompany.com/heiq-plc/register-investor
Carlo Centonze, co-founder and CEO, HeiQ plc, said:
"As we look forward, we cautiously anticipate market conditions to improve in the second half of 2024. Until this time, we will continue to remain vigilant, focusing on operational efficiencies and adapting our cost base.
"With resilience, innovation, and collaboration at our core, we are confident in our ability to overcome these obstacles and emerge stronger from these testing times. I extend my gratitude to our investors, team members, advisors, and customers for their unwavering support and dedication. Together, we will chart a path forward towards sustainable growth and success in 2024 and beyond."
For further information, please contact:
HeiQ Plc Carlo Centonze (CEO) |
+41 56 250 68 50 |
Cavendish Securities plc (Broker) Stephen Keys / Callum Davidson |
+44 (0) 207 397 8900 |
SEC Newgate (Media Enquiries) Elisabeth Cowell / Molly Gretton / Tom Carnegie |
+44 (0) 20 3757 6882 |
About HeiQ
HeiQ is a Swiss-based international company that innovates pioneering and differentiating materials in partnership with established global brands. We bridge the academic and commercial worlds to conceive performance-enhancing materials and technologies, working with aligned brands to research, manufacture and bring products to market, aiming for lab to consumer in months. Our goal is to improve the lives of billions by innovating the materials that go into everyday products, making them more hygienic, comfortable, protective, and sustainable.
Our strong IP portfolio positions us as an innovation leader for niche, premium and high-margin products in the textile chemicals, man-made fibers, paints and coatings, antimicrobial plastics, probiotics and household cleaner markets. We have also expanded into healthcare facilities, probiotic cleaning, and hygiene coatings markets to help make hospitals and healthcare environments more hygienic.
We have developed over 200 technologies in partnership with 300 major brands. With a substantial research and development pipeline, including key technology development projects HeiQ AeoniQ, HeiQ ECOS, HeiQ GrapheneX, and HeiQ Synbio, HeiQ aims to deliver shareholder value through sales growth and entry into new lucrative markets through disruptive innovation and M&A.
We have built a strong reputation for ESG & sustainable innovation, having won multiple awards including the Swiss Technology Award twice and the Swiss Environmental Award. Under experienced leadership, we are committed to driving our profit in close connection with people and the planet. For more information, please visit www.heiq.com.
The market downturn which commenced in late 2022 continued to cause challenges for HeiQ throughout 2023. Contrary to predictions by many in the industry, market conditions failed to rebound during the period. Our revenues decreased by 11.6% to US$42 million for the twelve months ending December 31, 2023, primarily driven by historically high inventories, and weak industry demand. In response, we implemented measures to adjust our cost base and organizational structure, while maintaining HeiQ's innovation and differentiation capabilities. Despite the extremely challenging market conditions during the period for HeiQ's growth-oriented business units, we made significant progress with our exciting and potentially game-changing venture initiatives HeiQ AeoniQ, HeiQ GrapheneX and HeiQ ECOS.
In light of the challenges faced during the year, we are greatly appreciative of the support shown by our shareholders in our recent fundraise to support the Company's next phase of growth.
Strategy & Structure
Since listing on the London Stock Exchange on December 7, 2020, HeiQ has evolved significantly. Initially known as an innovation company with a focus on specialty chemicals for textile and flooring, HeiQ has since developed into a company with leading technology platforms that drive sustainability in strategic industries and applications.
This evolution means HeiQ, while still being recognized as a leader in textile performance chemicals and antimicrobials, today focuses are on sustainable technologies in textile fibres (HeiQ AeoniQ), probiotic healthcare cleaners (HeiQ Synbio), anode free solid state lithium metal batteries (HeiQ GrapheneX) and transparent conductive coatings (HeiQ ECOS). This evolution has been achieved both through acquisitions and HeiQ's own innovation and business development efforts.
HeiQ's organizational structure, consists of three distinct technology ventures alongside three growth-orientated business segments.
This Venture & Growth structure enables the organization to stay focused on growth and commercialization of existing as well as the incubation of new technologies. With dedicated teams for each unit, we can deploy and adjust resources and skills appropriate to the different maturity levels of the units.
Governance
The evolution of HeiQ over the last four years has led to a significant increase in administrative complexity, in turn, requiring our reporting processes and governance to evolve and improve. The Company acknowledges and is fully committed to implementing these improvements, and as such began making significant investments in 2023 to address them.
In Q1 2023, we established a central accounting function within our global shared service hub in Portugal to strengthen our financial reporting processes. This has since expanded to include 5 full-time equivalents (FTEs). We have also advanced the implementation of harmonizing our enterprise resource planning (ERP) systems across our group. These initiatives aim to improve the quality, efficiency, and governance of our financial reporting processes. This investment in our organization has had a limited impact on the 2022 financial reporting process, but we expect significant improvements for the 2023/24 financial reporting cycle.
To address the deficiencies identified by Deloitte LLP in auditing the 2022 accounts we have undertaken a comprehensive set of actions:
• We engaged Ernst & Young (EY) to support the improvement of governance, reporting and financial accounting processes.
• We are adding two additional employees to manage the EY governance project implementation and to strengthen the internal controls system on an ongoing basis.
• We defined a roadmap to address the most severe deficiencies and those which will have the greatest positive impact on the 2023/24 financial reporting process.
• We have already implemented improvements for this interim report as of December 31, 2023, as far as practicable.
As previously announced, the Company continues to seek a replacement auditor following the resignation of Deloitte LLP. The Company will update the market in due course.
The Company has extended its accounting reference date to June 30, to enable an incoming auditor to properly onboard and complete the audit in a reasonable timeframe. Therefore, this financial report represents unaudited interim financial statements for the 12-month period ending December 31, 2023. The Company's next set of audited financial reports and accounts will be for the period January 1, 2023 to June 30, 2024 and will be published by October 31, 2024.
Changes to the Board of Directors
On January 1, 2024, Robert van de Kerkhof joined the Board of HeiQ plc as a non-executive director and chair of the Environmental, Occupation, Health & Safety and Sustainability Committee. With over 30 years' experience in management and sustainability leadership, including serving as Chief Commercial Officer, Chief Sustainability Officer and board member of the listed company Lenzing AG (Austria), Robert is a great addition to the Board.
As previously announced, I will retire as Chair and non-executive director of HeiQ plc on March 31, 2024. Joining the Company just before its listing in 2020, it has been an intense and very fulfilling time. Together with fellow directors and a dedicated management team, we have navigated through a myriad of challenges and opportunities, culminating in the development of a compelling portfolio of high-potential platform technologies poised to sustainably revolutionize growing industries.
As HeiQ enters the next stage of its growth with the commercial launch and scaling of its venture technologies, I have concluded it is an appropriate moment to hand-over the Chair position. This will allow me to spend more time with my family while ensuring HeiQ has a new leader with exceptional experience and industry knowledge.
Following the proposal by the Nomination Committee after a thorough selection process, the Board of Directors has unanimously appointed Robert van de Kerkhof as the new Chair of HeiQ plc, effective April 1, 2024.
I am convinced that HeiQ is in very capable hands with Robert as Chair, as he is not only a technical expert, but also an exceptional leader with executive management experience on listed company boards.
I thank the entire HeiQ team for the last four years and extend my best wishes to all HeiQans, our investors as well as all our other stakeholders.
Esther Dale
Chair
March 28, 2024
I am pleased to provide an update on our company's performance for the twelve months ending December 31, 2023 and an outlook for 2024.
2023 continued to present challenges for our industry and commercialized businesses. Despite the strategic initiatives of relocation of capabilities, cost containment and strategic focus undertaken to mitigate the impact of market disruptions, our financial performance remained under pressure, especially as we kept investing in our venture innovation platforms. Sales for the year amounted to US$41.7 million, reflecting a -11.6% decrease compared to the previous year. We continued to face margin pressure in a buyers-market driven by current overcapacity and historically high inventories at brands.
Operating losses persisted in 2023, albeit with some improvement, amounting to US$11.6 million for the twelve months ending December 31, 2023. The ongoing macroeconomic uncertainties, coupled with the challenges in securing committed credit facilities, contributed to the financial constraints faced by the company.
Innovation remains the cornerstone of our company's strategy, driving sustainable growth and differentiation in the market. We made significant strides in advancing our key commercial and venture innovation platforms in 2023:
· HeiQ AeoniQ, the world's first climate positive cellulosic filament fibre, launched to the market with Hugo Boss in 2023. Tennis star Matteo Berrettini featured the first t-shirt during the Australian Open 2023, and Hugo Boss prominently displayed a state-of-the-art fashion collection called "The Change" at the Milano Fashion Show. The uniqueness of HeiQ AeoniQ was awarded an ISPO award for product of the year. In Q1 2024 HeiQ purchased a large industrial plot of 25,000m2 in Portugal to build its first 3,000-ton HeiQ AeoniQ plant by 2026. Joining Hugo Boss, MAS Holdings, one of world's leading garment makers, co-invested into HeiQ AeoniQ. HeiQ AeoniQ secured an initial grant of EUR10 million from the Portuguese government and was given the status as a project of national strategic importance. We were delighted to appoint Julien Born, former CEO of The Lycra Company to lead HeiQ AeoniQ as CEO and Robert van de Kerkhof, former CCO/CSO of Lenzing, to act as its Chair.
· HeiQ ECOS, our transparent conductive coating technology platform, progressed well in application development with market leaders in thin film insulation for rapid retrofitting and energy efficiency improvement of buildings, climate control in advanced greenhouse foils, transparent car window heating, signature management for defence applications, as well as conductive layering for novel organic photovoltaics. We expect several of these potential applications to become first market prototypes in 2024.
· HeiQ GrapheneX, our highly porous graphene membrane, has secured its first external innovation funding from an electronics technology partner and progressed to demonstrate the performance benefits of its novel graphene membrane in building an anode-free solid-state lithium metal battery with double energy density. Considerable new IP was gained and is being filed in patent applications. In 2024 the first pilot commercialization plant will be commissioned in Switzerland, bringing the technology from the lab to the work floor.
· HeiQ Synbio, our biotech & life sciences platform, progressed rapidly in 2023 with the completion of the study conducted by the Charité University Hospital Berlin, sponsored by the German Government and the Bill and Melinda Gates Foundation. It established that probiotic HeiQ Synbio hospital cleaners perform equally well as Ecolab disinfectants but additionally prevent the formation of pathogens' multi-resistance buildup. Based on these stark results, the Robert Koch Institute recommended probiotic cleaners to German hospitals. The European Commission added probiotic cleaners to its new detergent regulation draft having previously awarded probiotic cleaners the EU Ecolabel. We therefore expect strong growth for our HeiQ Synbio platform in the years to come.
As we look ahead to 2024, we anticipate a continuation of the challenging market conditions experienced in 2023 during the first half of the year. The global economy remains uncertain, with ongoing geopolitical tensions and supply chain disruptions affecting various industries. However, as of today, we expect market conditions to start improving in H2 2024.
Considering the persisting challenges, focus for 2024 remains on:
· Lean Adaptation: Remaining agile and adaptive to changing market dynamics and consumer behaviours.
· Operational Efficiency: Continued emphasis on cost optimization measures to improve operational efficiency and preserve financial stability as well as liquidity.
· Innovation and Differentiation: Prioritizing rapid innovation initiatives that offer differentiation in the market and address evolving customer needs.
· Market Expansion: Exploring opportunities for market expansion in resilient sectors and geographies, while also strengthening existing partnerships.
· Sustainability: Upholding our commitment to sustainability by advancing our innovation initiatives that reduce environmental impact and promote responsible business practices.
As we navigate through present-day challenges and uncertainties of the current market landscape, we remain steadfast in our commitment to delivering long-term value for our shareholders, customers, and stakeholders. With resilience, innovation, and collaboration, we are confident in our ability to raise again and overcome obstacles and emerge stronger from these testing times.
I extend my gratitude to our investors, team members, advisors, and customers for their unwavering support and dedication. Together, we will chart a path forward towards sustainable growth and success in 2024 and beyond.
Carlo Centonze
CEO & Executive Director
March 28, 2024
The Group has an established, structured approach to identifying and assessing the impact of financial and operational risks on its business. The principal risks and uncertainties for the remainder of the financial year are not expected to change materially from those included on pages 38 to 42 of the Annual Report and Accounts 2022. The risks identified relate to the following areas: Delivery on growth strategy; Increase in competition; Geographical risks; IP protection and first mover advantage; Regulatory risks; Reputational risks and failure to build brand equity; Innovation pipeline; Supply chain disruptions; Personnel/Workforce; Interruption of IT system operations; Liquidity risk; currency risks; Product liability. Further information in relation to the Group's financial position and going concern is included in note 2.
Carlo Centonze
CEO & Executive Director
March 28, 2024
As outlined in the Chairwoman's statement and the Business Report, 2023 was a very challenging year for the Company. The continuously weak market conditions for our main commercial businesses led to a decrease in revenues for the 12-month period by -11.6% to US$41.7 million (2022: US$47.2 million).
Gross profit of US$15.5 million (2022: US$13.5 million) represents a gross margin on sales of 37.0% (2022: 28.5%). While this represents an overall recovery of 8.5%, it was impacted by increased allowances on inventory to reflect the continuing weak market demand. Excluding this impact, the gross margin would be 41.2% for the period.
Total selling, general and administrative expenses (SG&A) were US$29.6 million for the 12months ending December 31, 2023, representing an overall decrease of 4.5% versus the prior year period (2022: US$31.0 million). Personnel expenses accounted for 44.9% of total SG&A costs in 2023 and amount to US$13.3 million - down -11.3% (US$-1.7 million) compared to the same period in 2022 (US$15.0 million). A significant portion of SG&A is related to our venture initiatives and thus represents capability building development costs. In 2023 SG&A expenses of about US$2.5 million relate to our venture initiatives and thus represents capability building development costs.
Accounting aspects relying on significant judgment and estimations and individual transactions that materially affected our interim financial statements as of December 31, 2023, are as follows:
Allowance on inventory
In line with existing accounting policies of the Company, an inventory allowance of US$1.8 million was recorded within cost of sales. The allowance relates mainly to excess inventory positions. Based on the continuing weak market conditions, for a limited number of inventory items the Board has concluded that it is not certain that all inventory on hand can be sold within the foreseeable future and therefore has determined this allowance to be appropriate.
Impairment of intangible assets
The Company acquired in previous years certain intangible assets to secure its intellectual property position in relation to certain long-term customer contracts, including the exclusivity agreement with ICP Industrial Inc. As the exclusive agreement with ICP has been terminated, the Directors have deemed it appropriate to write-off the corresponding intangible assets, amounting in a write-off of US$1.1 million in 2023.
Settlement of litigation
As announced in November 2023, the Group settled the litigation and the termination of an exclusive agreement between its subsidiary HeiQ Materials AG and ICP Industrial Inc. ("ICP"). The settlement of the litigation included dismissal of claims and counterclaims by both parties with prejudice and ICP agreed to pay HeiQ Plc a total of US$2.75 million, which was received in December 2023. The settlement payment is accounted for as "Other income" within the operating loss.
All the above contributed to a loss from operations for the 12 months ending December 31, 2023 of US$11.6 million (2022: US$29.2 million).
Results |
For the six months ended December 31, |
For the year ended December 31 |
|
||
|
2023 |
2022 |
2023 |
2022 |
|
|
US$'000 |
US$'000 |
US$'000 |
US$'000 |
|
Revenue |
21,247 |
19,644 |
41,747 |
47,202 |
|
Cost of sales |
(14,177) |
(17,618) |
(26,287) |
(33,745) |
|
Gross profit |
7,070 |
2,026 |
15,460 |
13,457 |
|
Other income |
3,284 |
2,084 |
4,230 |
4,832 |
|
Selling and general administrative expenses |
(15,319) |
(16,953) |
(29,582) |
(30,969) |
|
Impairment reversal/(loss) on intangible assets |
90 |
(11,651) |
90 |
(11,651) |
|
Impairment loss on property, plant & equipment |
(84) |
(730) |
(84) |
(730) |
|
Other expenses |
(623) |
(2,449) |
(1,698) |
(4,184) |
|
Operating loss |
(5,582) |
(27,673) |
(11,584) |
(29,245) |
|
Depreciation of property, plant and equipment |
742 |
638 |
1,453 |
1,282 |
|
Amortization of intangible assets |
1,134 |
769 |
2,203 |
1,435 |
|
Depreciation of right-of-use assets |
527 |
441 |
1,005 |
938 |
|
Impairment losses and write-offs |
1,396 |
13,278 |
1,396 |
13,278 |
|
Share options and rights granted to |
202 |
(348) |
334 |
138 |
|
Adjusted EBITDA |
(1,581) |
(12,895) |
(5,193) |
(12,174) |
|
EBITDA Margin (adjusted) |
(7.4%) |
(65.6%) |
(12.4%) |
(25.8%) |
|
Cashflow from operating activities
Liquidity and cashflow is a key focus for the Company in these challenging circumstances. We have undertaken decisive steps to reduce the cash-use of operating activities during the period. As a result, the Company managed to return to a positive cashflow from operating activities in H2 2023:
US$'000 |
Jul - Dec |
Jan - Jun |
Jul - Dec |
Jan - Jun |
|
|
Net cash from (used in) operating activities |
1,505 |
(4,799) |
(486) |
(1,973) |
Inventory & Trade receivables
Both inventory and trade receivables were significantly reduced during the reporting period. As of December 31, 2023, inventory was valued at US$11.3 million which represents a reduction of -14.6% (2022: US$13.2 million). Trade receivables of US$5.7 million represent a reduction of 12.5% (2022: US$6.5 million).
Post balance sheet date events
In February 2024 the Group completed the acquisition of two industrial properties in Portugal for a total consideration of EUR5.0 million (including taxes) which we believe represented a significant discount to market prices for similar properties. To secure the price and to finance the acquisition, the Company received bridge financing from Cortegrande AG, a company owned by the Group CEO Carlo Centonze. In late March 2024, the Group secured a mortgage of EUR0.75 million for the smaller lot acquired at a price (before taxes) of EUR1.0 million while negotiations for the large lot (acquisition price before tax EUR3.6 million) with the mortgage provider are ongoing. Further, in March 2024 the Company completed a capital raise issuing 28 million new shares for a total consideration of £2.4 million (£0.087 per share).
Liquidity as of December 31, 2023 & Going Concern Assessment
As of December 31, 2023, the Company's cash balance was US$9.7 million (December 31, 2022: US$8.5 million) and net debt position including lease liabilities was US$-10.0 million as of December 31, 2023 (2022: US$-3.7 million). To manage its cash balance, the Group has access to credit facilities totalling CHF8.8 million (approximately US$9.9 million as of March 28, 2023). The credit facilities are in place with two different banks and both contracts have materially the same conditions. The facilities are not limited in time, can be terminated by either party at any time and allow overdrafts and fixed cash advances with a duration of up to twelve months.
As of March 28, 2023, the Group has drawn fixed cash advances amounting to CHF7.8 million and EUR0.4 million (December 31, 2022: CHF2.4 million) - see Note 2 for details including maturity dates. The facilities are not committed, but the Board has not received any indication from financing partners that facilities are at risk of being terminated. However, the credit facilities will be reduced by CHF0.3 million to CHF8.5 million in total as of June 17, 2024.
The Group's directors have a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future and operate within its credit facilities for the period of 12 months from date of signature. Nevertheless, the Board acknowledges the uncommitted status of the facilities which could be terminated requiring the refinancing of debts, and which casts material uncertainty on the going concern assessment until appropriate longer-term funding is in place. Further disclosures on the going concern assessment are made in the notes to the financial statements.
Xaver Hangartner
CFO & Executive Director
March 28, 2024
|
|
|
|
|
For the six months ended December 31, |
|
For the year ended December 31, |
|
||
|
|
|
|
|
2023 |
2022 |
|
2023 |
2022 |
|
|
|
|
|
|
(Unaudited) |
(Unaudited) |
|
(Unaudited) |
(Audited) |
|
|
Note |
|
|
|
US$'000 |
US$'000 |
|
US$'000 |
US$'000 |
|
Revenue |
5 |
|
|
|
21,247 |
19,644 |
|
41,747 |
47,202 |
|
Cost of sales |
7 |
|
|
|
(14,177) |
(17,618) |
|
(26,287) |
(33,745) |
|
Gross profit |
|
|
|
|
7,070 |
2,026 |
|
15,460 |
13,457 |
|
Other income |
8 |
|
|
|
3,284 |
2,084 |
|
4,230 |
4,832 |
|
Selling and general administrative expenses |
9 |
|
|
|
(15,319) |
(16,953) |
|
(29,582) |
(30,969) |
|
Impairment reversal/(loss) on intangible assets |
16 |
|
|
|
90 |
(11,651) |
|
90 |
(11,651) |
|
Impairment loss on property, plant & equipment |
17 |
|
|
|
(84) |
(730) |
|
(84) |
(730) |
|
Other expenses |
11 |
|
|
|
(623) |
(2,449) |
|
(1,698) |
(4,184) |
|
Operating loss |
|
|
|
|
(5,582) |
(27,673) |
|
(11,584) |
(29,245) |
|
Finance income |
12 |
|
|
|
69 |
241 |
|
74 |
683 |
|
Finance costs |
13 |
|
|
|
(1,055) |
(749) |
|
(1,439) |
(1,273) |
|
Loss before taxation |
|
|
|
|
(6,568) |
(28,181) |
|
(12,949) |
(29,835) |
|
Income tax |
14 |
|
|
|
(884) |
275 |
|
(1,030) |
21 |
|
Loss after taxation |
|
|
|
|
(7,452) |
(27,906) |
|
(13,979) |
(29,814) |
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income: |
|
|
|
|
|
|
|
|
|
|
Exchange differences on translation of foreign operations |
|
|
|
|
546 |
(824) |
|
975 |
(1,914) |
|
Items that may be reclassified to profit or loss in subsequent periods |
|
|
|
|
546 |
(824) |
|
975 |
(1,914) |
|
Actuarial gains/(losses) from defined benefit pension plans |
|
|
|
|
(218) |
1,380 |
|
(218) |
1,380 |
|
Income tax relating to items that will not be reclassified subsequently to profit or loss |
|
|
|
|
249 |
(276) |
|
249 |
(276) |
|
Items that will not be reclassified to profit or loss in subsequent periods |
|
|
|
|
31 |
1,104 |
|
31 |
1,104 |
|
Other comprehensive income (loss) for the period |
|
|
|
|
577 |
280 |
|
1,006 |
(810) |
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive loss for the period |
|
|
|
|
(6,875) |
(27,626) |
|
(12,973) |
(30,624) |
|
|
|
|
|
|
|
|
|
|
|
|
Loss attributable to: |
|
|
|
|
|
|
|
|
|
|
Equity holders of HeiQ |
|
|
|
|
(7,147) |
(27,546) |
|
(13,583) |
(29,251) |
|
Non-controlling interests |
|
|
|
|
(305) |
(360) |
|
(396) |
(563) |
|
|
|
|
|
|
(7,452) |
(27,906) |
|
(13,979) |
(29,814) |
|
Total Comprehensive loss attributable to: |
|
|
|
|
|
|
|
|
|
|
Equity holders of the Company |
|
|
|
|
(6,570) |
(27,266) |
|
(12,577) |
(30,061) |
|
Non-controlling interests |
|
|
|
|
(305) |
(360) |
|
(396) |
(563) |
|
|
|
|
|
|
(6,875) |
(27,626) |
|
(12,973) |
(30,624) |
|
Loss per share: |
|
|
|
|
|
|
|
|
|
|
Basic (cents) * |
15 |
|
|
|
(5.09) |
(20.39) |
|
(9.67) |
(21.92) |
|
*The effect of share options is anti-dilutive and therefore not disclosed.
|
|
|
As at December 31, 2023 (Unaudited) |
As at December 31, 2022 (Audited) |
|
Note |
|
US$'000 |
US$'000 |
ASSETS |
|
|
|
|
Intangible assets |
16 |
|
20,489 |
20,442 |
Property, plant and equipment |
17 |
|
9,003 |
9,802 |
Right-of-use assets |
18 |
|
8,132 |
7,819 |
Deferred tax assets |
30 |
|
312 |
538 |
Other non-current assets |
19 |
|
82 |
137 |
Non-current assets |
|
|
38,018 |
38,738 |
Inventories |
20 |
|
11,250 |
13,168 |
Trade receivables |
21 |
|
5,673 |
6,487 |
Other receivables and prepayments |
22 |
|
4,349 |
4,262 |
Cash and cash equivalents |
|
|
9,694 |
8,488 |
Current assets |
|
|
30,966 |
32,405 |
Total assets |
|
|
68,984 |
71,143 |
|
|
|
|
|
EQUITY AND LIABILITIES |
|
|
|
|
Issued share capital and share premium |
24 |
|
206,246 |
205,874 |
Other reserves |
26 |
|
(126,830) |
(128,017) |
Retained deficit |
|
|
(51,661) |
(39,466) |
Equity attributable to HeiQ shareholders |
|
|
27,755 |
38,391 |
Non-controlling interests |
|
|
1,728 |
1,948 |
Total equity |
|
|
29,483 |
40,339 |
Lease liabilities |
27 |
|
6,674 |
6,558 |
Long-term borrowings |
29 |
|
1,501 |
1,445 |
Deferred tax liability |
30 |
|
1,384 |
1,253 |
Other non-current liabilities |
31 |
|
5,010 |
4,714 |
Total non-current liabilities |
|
|
14,569 |
13,970 |
Trade and other payables |
32 |
|
6,672 |
5,322 |
Accrued liabilities |
33 |
|
4,483 |
4,978 |
Income tax liability |
14 |
|
606 |
314 |
Deferred revenue |
34 |
|
1,423 |
1,285 |
Short-term borrowings |
29 |
|
10,409 |
2,893 |
Lease liabilities |
27 |
|
1,131 |
1,264 |
Other current liabilities |
36 |
|
208 |
778 |
Total current liabilities |
|
|
24,932 |
16,834 |
Total liabilities |
|
|
39,501 |
30,804 |
Total equity and liabilities |
|
|
68,984 |
71,143 |
The Notes form an integral part of these Condensed Consolidated Interim Financial Statements. The Financial Statements were approved and authorized for issue by the Board of Directors on March 27, 2024 and signed on its behalf by:
Xaver Hangartner
CFO & Executive Director
|
|
|
|||||
|
|
Issued share capital and share premium |
Other reserves |
Retained deficit |
Equity attributable to HeiQ shareholders |
Non-controlling interests |
Total equity |
|
Note |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
Balance at January 1, 2022 (Audited) |
|
195,714 |
(127,195) |
(11,525) |
56,994 |
2,541 |
59,535 |
Loss after taxation |
|
- |
- |
(29,251) |
(29,251) |
(563) |
(29,814) |
Other comprehensive (loss)/income |
|
- |
(810) |
- |
(810) |
- |
(810) |
Total comprehensive (loss)/income for the period |
|
- |
(810) |
(29,251) |
(30,061) |
(563) |
(30,624) |
Issuance of shares |
24 |
10,160 |
- |
- |
10,160 |
- |
10,160 |
Share-based payment charges |
25 |
- |
(12) |
- |
(12) |
- |
(12) |
Dividends paid to minority shareholders |
26 |
- |
- |
- |
- |
(243) |
(243) |
Capital contributions from minority shareholders |
|
- |
- |
- |
- |
764 |
764 |
Adjustments arising from change in non-controlling interests |
|
- |
- |
(2,445) |
(2,445) |
(616) |
(3,061) |
Transfer on disposal of non-controlling interest |
|
- |
- |
3,755 |
3,755 |
65 |
3,820 |
Transactions with owners |
|
10,160 |
(12) |
1,310 |
11,458 |
(30) |
11,428 |
Balance at December 31, 2022 (Audited) |
|
205,874 |
(128,017) |
(39,466) |
38,391 |
1,948 |
40,339 |
|
|
|
|
|
|
|
|
Loss after taxation |
|
- |
- |
(13,583) |
(13,583) |
(396) |
(13,979) |
Other comprehensive (loss)/income |
|
- |
1,006 |
- |
1,006 |
- |
1,006 |
Total comprehensive (loss)/income for the period |
|
- |
1,006 |
(13,583) |
(12,577) |
(396) |
(12,973) |
Issuance of shares |
24 |
372 |
- |
- |
372 |
- |
372 |
Share-based payment charges |
25 |
- |
181 |
- |
181 |
- |
181 |
Elimination of non-controlling interest at disposal of subsidiary |
4b |
- |
- |
- |
- |
73 |
73 |
Dividends paid to minority shareholders |
26 |
- |
- |
- |
- |
(12) |
(12) |
Transfer of shares to non-controlling interest |
4c |
- |
- |
1,388 |
1,388 |
115 |
1,503 |
Transactions with owners |
|
372 |
181 |
1,388 |
1,941 |
176 |
2,117 |
Balance at December 31, 2023 (Unaudited) |
|
206,246 |
(126,830) |
(51,661) |
27,755 |
1,728 |
29,483 |
|
|
|
Six months ended December 31, |
|
Year ended December 31, |
||
|
|
|
2023 |
2022 |
|
2023 |
2022 |
|
|
|
(Unaudited) |
(Unaudited) |
|
(Unaudited) |
(Audited) |
|
Note |
|
US$'000 |
US$'000 |
|
US$'000 |
US$'000 |
Cash flows from operating activities |
|
|
|
|
|
|
|
Loss before taxation |
|
|
(6,568) |
(28,181) |
|
(12,949) |
(29,835) |
Cash flow from operations reconciliation: |
|
|
|
|
|
|
|
Depreciation and amortization |
16-18 |
|
2,403 |
1,848 |
|
4,661 |
3,655 |
Impairment expense |
16-17 |
|
(6) |
12,380 |
|
(6) |
12,380 |
Net loss/gain on disposal of assets |
|
|
67 |
(8) |
|
84 |
(5) |
Write-off of intangible assets |
11 |
|
1,388 |
897 |
|
1,402 |
897 |
Gain from disposal of subsidiary |
4b |
|
(138) |
- |
|
(138) |
|
Fair value gain on derivative liability |
8 |
|
(453) |
(371) |
|
(701) |
(371) |
Finance costs |
|
|
300 |
149 |
|
517 |
273 |
Finance income |
|
|
(29) |
(1) |
|
(34) |
(2) |
Pension expense |
|
|
(389) |
130 |
|
(346) |
247 |
Non-cash equity compensation |
25 |
|
202 |
(348) |
|
334 |
138 |
Gain from lease modification |
|
|
(6) |
- |
|
(15) |
(68) |
Other costs paid in shares |
24 |
|
- |
235 |
|
- |
235 |
Currency translation |
|
|
916 |
623 |
|
322 |
(61) |
Working capital adjustments: |
|
|
|
|
|
|
|
Decrease in inventories |
39 |
|
3,164 |
3,016 |
|
1,926 |
602 |
Decrease in trade and other receivables |
39 |
|
2,350 |
9,391 |
|
733 |
7,783 |
(Decrease)/Increase in trade and other payables |
39 |
|
(1,798) |
95 |
|
1320 |
2,543 |
Cash from (used in) operations |
|
|
1,403 |
(145) |
|
(2,890) |
(1,589) |
Taxes paid |
14 |
|
102 |
(341) |
|
(404) |
(870) |
Net cash from (used in) operating activities |
|
|
1,505 |
(486) |
|
(3,294) |
(2,459) |
Cash flows from investing activities |
|
|
|
|
|
|
|
Consideration for acquisition of businesses |
39 |
|
(730) |
- |
|
(730) |
(1,587) |
Cash assumed in asset acquisition |
39 |
|
10 |
65 |
|
12 |
65 |
Disposal of a subsidiary, net of cash disposed of |
4b |
|
(24) |
- |
|
(24) |
- |
Purchase of property, plant and equipment |
17 |
|
(829) |
(2,358) |
|
(1,413) |
(3,418) |
Proceeds from the disposal of property, plant and equipment |
|
|
29 |
16 |
|
844 |
53 |
Development and acquisition of intangible assets |
16 |
|
(484) |
(1,919) |
|
(1,149) |
(3,865) |
Interest received |
|
|
29 |
1 |
|
34 |
2 |
Net cash used in investing activities |
|
|
(1,999) |
(4,195) |
|
(2,426) |
(8,750) |
Cash flows from financing activities |
|
|
|
|
|
|
|
Interest paid on borrowings |
|
|
(190) |
(68) |
|
(312) |
(110) |
Repayment of leases |
|
|
(682) |
(540) |
|
(1,296) |
(992) |
Interest paid on leases |
|
|
(110) |
(81) |
|
(205) |
(163) |
Proceeds from disposals of minority interests |
|
|
1,504 |
2,333 |
|
1,504 |
4,792 |
Proceeds from borrowings |
27 |
|
2,964 |
2,642 |
|
7,962 |
3,465 |
Repayment of borrowings |
27 |
|
(693) |
(707) |
|
(958) |
(904) |
Dividends paid to minority shareholders |
26 |
|
(12) |
- |
|
(12) |
(243) |
Net cash from financing activities |
|
|
2,781 |
3,579 |
|
6,683 |
5,845 |
Net decrease in cash and cash equivalents |
|
|
2,287 |
(1,102) |
|
963 |
(5,364) |
Cash and cash equivalents - beginning of the period/year |
|
|
7,274 |
9,488 |
|
8,488 |
14,560 |
Effects of exchange rate changes on the balance of cash held in foreign currencies |
|
|
133 |
102 |
|
243 |
(708) |
Cash and cash equivalents - end of the period |
|
|
9,694 |
8,488 |
|
9,694 |
8,488 |
HeiQ Plc (the Company) is a company limited by shares incorporated and registered in the United Kingdom. The address of the Company's registered office is 5th Floor, 15 Whitehall, London, SW1A 2DD.
These financial statements are presented in United States Dollars (US$) which is the presentation currency of the Group, and all values are rounded to the nearest thousand dollars except where otherwise indicated.
The Group extended its accounting reference date from December 31, to June 30, to enable the incoming auditor to properly onboard and complete the audit in a reasonable timeframe. The Company's next set of audited financial reports and accounts will be for the period January 1, 2023 to June 30, 2024 and will be published by October 31, 2024.
The unaudited condensed consolidated interim financial statements have been prepared in accordance with the Disclosure and Transparency Rules of the Financial Conduct Authority and UK adopted International Accounting Standard 34 "Interim Financial Reporting" (IAS 34). Other than as noted below, the accounting policies applied by the Group in the preparation of these interim financial statements are the same as those set out in the Company's audited financial statements for the year ended December 31, 2022. These financial statements have been prepared under the historical cost convention except for certain financial and equity instruments that have been measured at fair value.
These condensed financial statements do not include all of the information required for a complete set of IFRS financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Company's financial position and performance since the audited financial statements for the year ended December 31, 2022.
Statutory accounts for the year ended December 31, 2022 have been filed with the Registrar of Companies in October 2023 and the auditor's report was unqualified, did not contain any statement under Section 498(2) or 498(3) of the Companies Act 2006, and contained a matter (material uncertainty in regards to the going concern assumption) to which the auditors drew attention without qualifying their report.
The condensed interim financial statements are unaudited and have not been reviewed by the auditors and were approved by the Board of Directors on March 27, 2024.
The unaudited condensed consolidated interim financial statements have been prepared on a going concern basis, which contemplates the continuity of normal business activity and the realization of the assets and the settlement of liabilities in the normal course of business.
To manage its cash balance, the Group has access to credit facilities totalling CHF8.80 million (approximately US$9.9 million as of March 28, 2023). The credit facilities are in place with two different banks but with materially the same conditions. The facilities are not limited in time, can be terminated by either party at any time and allow overdrafts and fixed cash advances with a duration of up to twelve months. In case one or the other party terminates the agreement, fixed cash advances become due upon their defined maturity date. The facilities do not contain financial covenants, but they do require the delivery of certain financial and operational information within a defined timeframe after the balance sheet date.
As of March 28, 2024, the Group has drawn fixed advances amounting to CHF7.8 million and EUR0.4 million (CHF2.4 million as December 31, 2022) as follows:
Term / Maturity date |
CHF |
April 26, 2024 |
5.5 million |
April 15, 2024 |
0.5 million |
June 17, 2024 |
0.8 million |
September 30, 2024 |
1.0 million |
Term / Maturity date |
EUR |
April 02, 2024 |
0.4 million |
The Group's forecasts and projections for the next 12 months reflect the very challenging trading environment and show that the Group should be able to operate within the level of its current facility for at least 12 months from the date of signature of these financial statements if the facility drawdowns remain available. While the facilities are not committed, the Board has not received any indication from financing partners that the facilities are at risk of being terminated. However, the credit facilities will be reduced by CHF0.3 million to CHF8.5 million in total as of June 17, 2024.
The Board acknowledges the uncommitted status of the facilities which could be terminated without notice during the forecast period requiring the refinancing of debts as per above maturity date indicates that a material uncertainty exists that may cast significant doubt on the Group's and Parent Company's ability to continue as a going concern, and therefore the Group may not be able to realize its assets and discharge its liabilities in the normal course of business.
After considering the forecasts, sensitivities, and mitigating actions available to management and having regard to the risks and uncertainties to which the Group is exposed (including the material uncertainty referred to above), the Group's directors have a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future and operate within its credit facilities for the period 12 months from date of signature. Accordingly, the financial statements continue to be prepared on a going concern basis.
The Condensed Consolidated Financial Statements comprise the financial statements of the Company and its subsidiaries. Business combinations are accounted for under the acquisition method.
The following new standards and amendments were effective for the first time in these financial statements but did not have a material effect on the Group:
• Disclosure of Accounting Policies (Amendments to IAS 1 and IFRS Practice Statement 2);
• Classification of Liabilities as Current or Non-current (Amendments to IAS 1);
• Definition of Accounting Estimates (Amendments to IAS 8); and
• Deferred Tax Related to Assets and Liabilities arising from a Single Transaction (Amendments to IAS 12).
The Company has applied the same accounting policies and methods of computation in its interim consolidated financial statements as in its 2022 financial statements.
New and amended standards and Interpretations issued by the IASB that will apply for the first time in the next annual financial statements are not expected to impact the Group as they are either not relevant to the Group's activities or require accounting which is consistent with the Group's current accounting policies.
There have been no material revisions to the nature and amounts of estimates of amounts reported in prior periods.
On January 12, 2023, HeiQ Plc, completed the acquisition of the entire issued share capital of Tarn-Pure Holdings Ltd ("Tarn-Pure"). Tarn-Pure is a UK-based intellectual property company holding critical EU and UK regulatory registrations to sell elemental copper and elemental silver for use in disinfecting hygiene applications. The regulatory registrations of Tarn-Pure are critical to HeiQ to ensure regulatory compliance of its antimicrobial products long term. To acquire Tarn-Pure, HeiQ paid the vendors £530,000 (approximately US$621,000) in cash with an additional £317,000 (approximately US$372,000) satisfied through the issuance of 455,435 new ordinary shares of 30p each in the Company (the "Consideration Shares"), issued at a price of 69.6p per share. A further US$244,000 of deferred consideration is payable in cash in monthly instalments from February 2023 to February 2025. The purchase price allocation has not been finalized yet and is subject to possible changes in valuation of the assets acquired. it will be completed in the 2023/2024 annual report.
The following table provides an overview of the preliminary purchase price allocation. It summarizes the consideration paid, the fair value of assets acquired, liabilities assumed, and goodwill arising on acquisition at the acquisition date.
Preliminary purchase price allocation |
US$'000 |
Consideration: |
|
Cash paid to shareholders |
621 |
Shares issued to shareholders |
372 |
Deferred consideration |
244 |
Total Consideration |
1,237 |
|
|
Fair value of net assets acquired: |
|
Inventory |
13 |
Cash and cash equivalents |
12 |
Trade and other receivables |
12 |
Borrowings |
(42) |
Intangible assets identified on acquisition: |
|
Customer Relationship |
123 |
Regulatory asset |
682 |
Deferred tax liability on intangible assets |
(201) |
Total net assets |
599 |
Goodwill |
638 |
Total |
1,237 |
In July 2023, the Group sold 31% of its share in Life Materials Latam Ltda, Brazil for a consideration of US$nil. The Group's stake was reduced to 20% and, as a result, the company is no longer consolidated.
In July 2023, HeiQ Materials AG reached an agreement with MAS to dispose of 1.5% of its shareholding in HeiQ AeoniQ GmbH.
The Group founded HeiQ AeoniQ Holding AG Switzerland, which resides at Parkstrasse 1, 5234 Villigen. As at December 31, 2023, the Group holds 97% ownership.
The Group's focus on materials innovation which includes scientific research, manufacturing and consumer ingredient branding. The primary source of revenue is the production and sale of functional ingredients, materials and finished goods. Other sources of revenue include research and development, take-or-pay and exclusivity services.
The following table reconciles HeiQ Group's revenue for the periods presented:
|
For the six months ended December 31, |
For the year ended December 31, |
||
|
2023 |
2022 |
2023 |
2022 |
Revenue by type of product |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
Revenue recognized at point in time |
|
|
|
|
Functional ingredients |
16,376 |
15,019 |
32,123 |
36,175 |
Functional materials |
197 |
1,566 |
743 |
2,000 |
Functional consumer goods |
2,680 |
1,785 |
5,382 |
6,827 |
Services |
189 |
- |
1,169 |
160 |
Revenue recognized over time |
|
|
|
|
Services |
1,805 |
1,274 |
2,330 |
2,040 |
Total revenue |
21,247 |
19,644 |
41,747 |
47,202 |
The transaction prices allocated to unsatisfied and partially unsatisfied obligations at December 31, 2023 are as set out below:
|
|
|
As at December 31, 2023 |
As at December 31, 2022 |
Unsatisfied performance obligations |
|
|
US$'000 |
US$'000 |
Exclusivity services |
|
|
1,500 |
2,100 |
Research and development services |
|
|
3,360 |
3,750 |
Total unsatisfied performance obligations |
|
|
4,860 |
5,850 |
Management expects that 25 per cent of the transaction price allocated to the unsatisfied contracts as of 31 December 2023 will be recognized as revenue during 2024 (US$1.2 million). The remaining 75 per cent, US$3.7 million, will be recognized in 2025 (US$1.1 million) and 2026 financial year (US$2.6 million).
Contract assets and contract liabilities are disclosed under Note 23 and Note 35, respectively. Impairment losses recognized on any receivables or contract assets arising from the Group's contracts with customers are disclosed under Note 21 and Note 23, respectively.
Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Board of Directors of the Company.
For management purposes, the Group is organised into business units and the following reportable segments:
Segment |
Activity |
Textiles & Flooring |
Provide innovative ingredients to make textiles & flooring more functional, durable and sustainable. |
Life Sciences |
Offer biotech solutions to replace harmful biocides in domestic, commercial, healthcare and industrial usage, for a more balanced microbiome and environment. |
Antimicrobials |
Functionalize by enhancing hygiene of different hard surfaces in everyday products and our surroundings. |
Other activities |
All other activities of the Group including Innovation Services, Venture Business Development, and other non-allocated functions. |
In 2023 new overhead allocation rules were introduced and as a result more overhead costs were allocated to segments. 2022 segment revenue and profits are restated below using the new rules to allow for like for like comparison.
The following is an analysis of the Group's revenue and results by reportable segment:
Six months ended December 31, 2023 |
Textiles & Flooring |
Life Sciences |
Antimicrobials |
Other activities |
Total |
Revenue |
15,809 |
2,363 |
1,776 |
1,299 |
21,247 |
Operating loss |
(2,005) |
(1,019) |
584 |
(3,142) |
(5,582) |
Finance result |
|
|
|
|
(986) |
Loss before taxation |
|
|
|
|
(6,568) |
Taxation |
|
|
|
|
(884) |
Loss after taxation |
|
|
|
|
(7,452) |
Depreciation and amortization |
|
|
|
|
|
Property, plant and equipment |
282 |
190 |
23 |
247 |
742 |
Right-of use assets |
76 |
75 |
20 |
356 |
527 |
Intangible assets |
144 |
287 |
391 |
312 |
1,134 |
Impairment loss / (reversal) |
|
|
|
|
|
Property, plant and equipment |
- |
84 |
- |
- |
84 |
Intangible assets |
- |
- |
- |
(90) |
(90) |
Six months ended December 31, 2022 |
Textiles & Flooring |
Life Sciences |
Antimicrobials |
Other activities |
Total |
Revenue |
14,646 |
2,273 |
1,154 |
1,571 |
19,644 |
Operating loss |
(6,913) |
(5,000) |
(9,648) |
(6,112) |
(27,673) |
Finance result |
|
|
|
|
(508) |
Loss before taxation |
|
|
|
|
(28,181) |
Taxation |
|
|
|
|
275 |
Loss after taxation |
|
|
|
|
(27,906) |
Depreciation and amortization |
|
|
|
|
|
Property, plant and equipment |
126 |
162 |
11 |
339 |
638 |
Right-of use assets |
48 |
73 |
18 |
302 |
441 |
Intangible assets |
38 |
276 |
350 |
105 |
769 |
Impairment loss |
|
|
|
|
|
Property, plant and equipment |
- |
730 |
- |
- |
730 |
Intangible assets |
- |
2,402 |
8,247 |
1,002 |
11,651 |
Year ended December 31, 2023 |
Textiles & Flooring |
Life Sciences |
Antimicrobials |
Other activities |
Total |
Revenue |
31,340 |
4,842 |
2,940 |
2,625 |
41,747 |
Operating loss |
(888) |
(1,712) |
(1,126) |
(7,858) |
(11,584) |
Finance result |
|
|
|
|
(1,365) |
Loss before taxation |
|
|
|
|
(12,949) |
Taxation |
|
|
|
|
(1,030) |
Loss after taxation |
|
|
|
|
(13,979) |
Depreciation and amortization |
|
|
|
|
|
Property, plant and equipment |
580 |
361 |
38 |
474 |
1,453 |
Right-of use assets |
166 |
149 |
42 |
648 |
1,005 |
Intangible assets |
288 |
564 |
792 |
559 |
2,203 |
Impairment loss / (reversal) |
|
|
|
|
|
Property, plant and equipment |
- |
84 |
- |
- |
84 |
Intangible assets |
- |
- |
- |
(90) |
(90) |
Year ended December 31, 2022 |
Textiles & Flooring |
Life Sciences |
Antimicrobials |
Other activities |
Total |
Revenue |
34,184 |
6,164 |
4,182 |
2,672 |
47,202 |
Operating loss |
(4,231) |
(5,537) |
(10,116) |
(9,361) |
(29,245) |
Finance result |
|
|
|
|
(590) |
Loss before taxation |
|
|
|
|
(29,835) |
Taxation |
|
|
|
|
21 |
Loss after taxation |
|
|
|
|
(29,814) |
Depreciation and amortization |
|
|
|
|
|
Property, plant and equipment |
334 |
335 |
28 |
585 |
1,282 |
Right-of use assets |
123 |
145 |
42 |
628 |
938 |
Intangible assets |
74 |
550 |
699 |
112 |
1,435 |
Impairment loss |
|
|
|
|
|
Property, plant and equipment |
- |
730 |
- |
- |
730 |
Intangible assets |
- |
2,402 |
8,247 |
1,002 |
11,651 |
Segment revenue reported above represents revenue generated from external customers. There were no intersegment sales in the six months ended December 31, 2023 (2022: nil).
|
|
For the six months ended December 31, |
For the year ended December 31, |
||
|
|
2023 |
2022 |
2023 |
2022 |
Revenue by region |
|
US$'000 |
US$'000 |
US$'000 |
US$'000 |
North & South America |
|
9,010 |
9,327 |
18,704 |
20,425 |
Asia |
|
6,914 |
4,421 |
11,712 |
13,376 |
Europe |
|
5,243 |
5,782 |
11,091 |
13,109 |
Others |
|
80 |
114 |
240 |
292 |
Total revenue |
|
21,247 |
19,644 |
41,747 |
47,202 |
|
|
As at December 31, |
As at December 31, |
|
|
2023 |
2022 |
Non-current assets by region |
|
US$'000 |
US$'000 |
Europe |
|
27,767 |
22,290 |
Asia |
|
2,370 |
8,102 |
North & South America |
|
7,512 |
7,734 |
Others |
|
369 |
612 |
Total non-current assets |
|
38,018 |
38,738 |
During the six months ended December 31, 2023, no customers individually totalled more than 10% of total revenues (2022: none).
|
|
For the six months ended December 31, |
For the year ended December 31, |
|
||
|
|
2023 |
2022 |
2023 |
2022 |
|
Cost of sales |
|
US$'000 |
US$'000 |
US$'000 |
US$'000 |
|
Material expenses |
|
8,003 |
8,829 |
18,354 |
20,942 |
|
Personnel expenses |
|
1,689 |
1,354 |
3,252 |
2,830 |
|
Depreciation of property, plant and equipment |
|
291 |
310 |
643 |
652 |
|
Other costs of sales |
|
4,194 |
7,125 |
4,038 |
9,321 |
|
Total cost of sales |
|
14,177 |
17,618 |
26,287 |
33,745 |
|
Other costs of goods sold include freight and custom costs, warehousing and allowances on inventory.
|
|
For the six months ended December 31, |
For the year ended December 31, |
||
|
|
2023 |
2022 |
2023 |
2022 |
Other income |
|
US$'000 |
US$'000 |
US$'000 |
US$'000 |
Gain on disposal of property plant and equipment |
|
9 |
12 |
21 |
21 |
Gain on disposal of investments |
|
138 |
- |
138 |
- |
Foreign exchange gains |
|
(517) |
1,205 |
- |
3,539 |
Fair value gain on derivative liabilities |
|
453 |
371 |
701 |
371 |
Income from out-of-court settlement |
|
2,750 |
- |
2,750 |
- |
Other income |
|
451 |
496 |
620 |
901 |
Total other income |
|
3,284 |
2,084 |
4,230 |
4,832 |
In November 2023, the Group reached a settlement of the litigation with ICP, which includes dismissal of claims and counterclaims by both parties with prejudice. ICP has agreed to pay HeiQ Plc a total of USD $2.75 million. The settlement refers to a complaint filed by the Group in October 2022 for breaching its Exclusive Agreement terms.
Foreign exchange gains previously reported under other income have been reclassified to finance income (Note 12) during the 2023 reporting period so as to more fairly present the nature of such items.
Selling and general administration expenses |
|
For the six months ended December 31, |
For the year ended December 31, |
|
||
|
2023 |
2022 |
2023 |
2022 |
|
|
|
US$'000 |
US$'000 |
US$'000 |
US$'000 |
|
|
Personnel expenses |
|
6,442 |
7,169 |
13,291 |
14,977 |
|
Depreciation of property, plant and equipment |
|
451 |
328 |
810 |
630 |
|
Amortization of intangible assets |
|
1,134 |
769 |
2,203 |
1,435 |
|
Depreciation of right-of-use assets |
|
527 |
441 |
1,005 |
938 |
|
Net credit losses on financial assets and contract assets |
|
171 |
85 |
171 |
85 |
|
Other |
|
6,594 |
8,161 |
12,102 |
12,904 |
|
Total selling and general administration expenses |
|
15,319 |
16,953 |
29,582 |
30,969 |
|
Other selling and general administration expenses include costs for infrastructure, professional services and marketing as well as R&D and laboratory related costs, information technology & data expenses, sales representative & distribution expenses.
|
|
For the six months ended December 31, |
For the year ended December 31, |
||
|
|
2023 |
2022 |
2023 |
2022 |
Personnel expenses |
|
US$'000 |
US$'000 |
US$'000 |
US$'000 |
Wages & salaries |
|
7,323 |
7,344 |
14,547 |
15,274 |
Social security & other payroll taxes |
|
766 |
1,061 |
1,568 |
1,685 |
Pension costs |
|
(160) |
466 |
94 |
710 |
Share-based payments |
|
202 |
(348) |
334 |
138 |
Total personnel expenses |
|
8,131 |
8,523 |
16,543 |
17,807 |
Reported as cost of sales (Note 7) |
|
1,689 |
1,354 |
3,252 |
2,830 |
Reported as selling and general administration expense (Note 9) |
|
6,442 |
7,169 |
13,291 |
14,977 |
Total personnel expenses |
|
8,131 |
8,523 |
16,543 |
17,807 |
The pension costs for the six months ended December 31, 2023 were impacted by a curtailment gain (US$141,000) and further income from a plan amendment (US$341,000) as explained further in Note 28.
|
|
For the six months ended December 31, |
For the year ended December 31, |
||
|
|
2023 |
2022 |
2023 |
2022 |
Other expenses |
|
US$'000 |
US$'000 |
US$'000 |
US$'000 |
Foreign exchange losses |
|
(928) |
1,429 |
- |
3,050 |
Loss on disposal of property, plant and equipment |
|
76 |
5 |
105 |
16 |
Transaction costs relating to mergers and acquisitions |
|
- |
50 |
23 |
50 |
Write off intangible assets |
|
1,388 |
897 |
1,402 |
897 |
Other |
|
87 |
68 |
168 |
171 |
Total other expenses |
|
623 |
2,449 |
1,698 |
4,184 |
The write off mainly relates to patents acquired in view of the commercial partnership with ICP. As the partnership has been ended, the asset's economic benefits were consumed.
Foreign exchange losses previously reported under other expenses have been reclassified to finance costs (Note 13) during the 2023 reporting period so as to more fairly present the nature of such items.
|
|
For the six months ended December 31 |
For the year ended December 31, |
||
|
|
2023 |
2022 |
2023 |
2022 |
Finance income |
|
US$'000 |
US$'000 |
US$'000 |
US$'000 |
Interest income |
|
11 |
4 |
14 |
5 |
Gains on foreign currency transactions |
|
39 |
238 |
39 |
678 |
Other |
|
19 |
(1) |
21 |
- |
Total finance income |
|
69 |
241 |
74 |
683 |
|
|
For the six months ended December 31 |
For the year ended December 31, |
||
Finance costs |
|
2023 |
2022 |
2023 |
2022 |
|
US$'000 |
US$'000 |
US$'000 |
US$'000 |
|
Lease finance expense |
|
110 |
82 |
205 |
163 |
Interest on borrowings |
|
190 |
68 |
312 |
110 |
Bank fees |
|
104 |
65 |
271 |
98 |
Loss on foreign currency transactions |
|
651 |
534 |
651 |
902 |
Total finance costs |
|
1,055 |
749 |
1,439 |
1,273 |
The components of the provision for taxation on income included in the "Statement of profit or loss and other comprehensive income" are summarized below:
|
|
For the six months ended December 31 |
For the year ended December 31 |
|||
|
|
2023 |
2022 |
2023 |
2022 |
|
Current income tax expense |
|
US$'000 |
US$'000 |
US$'000 |
US$'000 |
|
Swiss corporate income taxes |
|
(70) |
28 |
(49) |
58 |
|
United States state and federal taxes |
|
355 |
10 |
456 |
393 |
|
Taiwan corporate income taxes |
|
73 |
40 |
154 |
118 |
|
Belgium corporate income taxes |
|
(53) |
(199) |
30 |
(123) |
|
Germany corporate income taxes |
|
(24) |
68 |
(24) |
51 |
|
Others |
|
34 |
(16) |
45 |
63 |
|
Total current income tax expense |
|
315 |
(69) |
612 |
560 |
|
Deferred income tax expense |
|
|
|
|
|
|
|
|
|
|
|
||
Switzerland |
|
698 |
159 |
676 |
90 |
|
United States |
|
(41) |
(535) |
(45) |
(606) |
|
China |
|
8 |
245 |
6 |
117 |
|
Austria |
|
5 |
24 |
3 |
20 |
|
Belgium |
|
(63) |
(65) |
(131) |
(136) |
|
Others |
|
(38) |
(34) |
(91) |
(66) |
|
Total deferred income tax expense (income) |
|
569 |
(206) |
418 |
(581) |
|
|
|
|
|
|
|
|
Total income tax expense (income) |
|
884 |
(275) |
1,030 |
(21) |
|
|
|
As at December 31, |
As at December 31, |
|
|
2023 |
2022 |
Net tax (assets)/liabilities |
US$'000 |
US$'000 |
|
Opening balance (prepaid taxes) |
|
(343) |
51 |
Assumed on asset acquisition |
|
- |
(32) |
Income tax expense for the year |
|
612 |
560 |
Taxes paid |
|
(404) |
(870) |
Foreign currency differences |
|
(5) |
(52) |
Net tax (asset)/liability |
|
(140) |
(343) |
|
|
|
|
|
|
As at December 31, |
As at December 31, |
|
|
2023 |
2022 |
Net tax (assets) liabilities |
US$'000 |
US$'000 |
|
Prepaid income taxes |
|
(746) |
(657) |
Income tax liabilities |
|
606 |
314 |
Net tax (asset)/liability |
|
(140) |
(343) |
The calculation of basic earnings per share is based on the following data:
|
For the six months ended December 31, |
For the year ended December 31, |
||
|
2023 |
2022 |
2023 |
2022 |
Loss attributable to the ordinary equity holders of the parent entity (US$'000) |
(7,147) |
(27,546) |
(13,583) |
(29,251) |
Weighted average number of ordinary shares for the purposes of basic earnings per share |
140,537,907 |
135,084,870 |
140,522,934 |
133,426,953 |
Basic loss per share (cents) |
(5.09) |
(20.39) |
(9.67) |
(21.92) |
The effect of share options is anti-dilutive and therefore not disclosed.
Basic earnings per share is calculated by dividing the profit/loss after tax attributable to the equity holders of the Company by the weighted average number of shares in issue during the year. The effect of share options is anti-dilutive and therefore not disclosed.
|
Goodwill |
Internally developed assets |
Brand names and customer relations |
Acquired technologies |
Other intangible assets |
Total |
Cost |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
As at January 1, 2022 |
21,382 |
3,509 |
4,503 |
3,180 |
2,332 |
34,906 |
Additions arising from internal development |
- |
2,165 |
- |
- |
- |
2,165 |
Other acquisitions |
- |
- |
- |
- |
1,700 |
1,700 |
Disposals / write-offs |
- |
(85) |
- |
- |
(812) |
(897) |
Currency translation differences |
(795) |
5 |
(160) |
(165) |
14 |
(1,101) |
As at December 31, 2022 |
20,587 |
5,594 |
4,343 |
3,015 |
3,234 |
36,773 |
Additions arising from internal development |
- |
1,006 |
- 123
|
- |
- |
1,006 |
Business combinations |
641 |
- |
123 |
-
|
682 |
1,446 |
Other acquisitions |
- |
- |
- |
- |
143 |
143 |
Disposals / write-offs |
- |
(228) |
- |
- |
(1,441) |
(1,669) |
Reclassifications |
- |
93 |
- |
- |
- |
93 |
Currency translation differences |
494 |
579 |
100 |
95 |
161 |
1,429 |
As at December 31, 2023 |
21,722 |
7,044 |
4,566 |
3,110 |
2,779 |
39,221 |
Amortization and accumulated impairment losses |
|
|
|
|||
As at January 1, 2022 |
2,305 |
474 |
602 |
234 |
518 |
4,133 |
Amortization for the year |
- |
198 |
695 |
334 |
208 |
1,435 |
Impairment loss |
10,576 |
880 |
73 |
- |
122 |
11,651 |
Currency translation differences |
(750) |
3 |
(72) |
(45) |
(24) |
(888) |
As at December 31, 2022 |
12,131 |
1,555 |
1,298 |
523 |
824 |
16,331 |
Amortization for the year |
- |
715 |
721 |
334 |
433 |
2,203 |
Disposals / write-offs |
- |
(25) |
- |
- |
(242) |
(267) |
Reclassifications |
- |
93 |
- |
. |
- |
93 |
Impairment loss |
- |
(90) |
- |
- |
- |
(90) |
Currency translation differences |
263 |
190 |
(9) |
(6) |
24 |
462 |
As at December 31, 2023 |
12,394 |
2,438 |
2,010 |
851 |
1,039 |
18,732 |
Net book value |
|
|
|
|
|
|
As at December 31, 2022 |
8,456 |
4,039 |
3,045 |
2,492 |
2,410 |
20,442 |
As at December 31, 2023 |
9,328 |
4,606 |
2,556 |
2,259 |
1,740 |
20,489 |
|
Machinery and equipment |
Motor vehicles |
Computers and software |
Furniture and fixtures |
Land and buildings |
Total |
Cost |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
As at January 1, 2022 |
7,288 |
536 |
914 |
474 |
1,523 |
10,735 |
Additions |
2,272 |
26 |
197 |
50 |
2,736 |
5,280 |
Disposals |
(69) |
(12) |
- |
- |
- |
(81) |
Reclassifications |
(407) |
59 |
- |
348 |
- |
- |
Currency translation differences |
(233) |
(1) |
(21) |
(23) |
(91) |
(369) |
As at December 31, 2022 |
8,851 |
608 |
1,090 |
849 |
4,168 |
15,566 |
Additions |
1,167 |
113 |
32 |
60 |
41 |
1,413 |
Disposals |
(976) |
(57) |
(8) |
(15) |
- |
(1,056) |
Reclassifications |
(37) |
- |
- |
37 |
- |
- |
Currency translation differences |
374 |
9 |
97 |
49 |
68 |
597 |
As at December 31, 2023 |
9,379 |
673 |
1,211 |
980 |
4,277 |
16,520 |
Depreciation and accumulated impairment losses |
|
|
|
|
||
As at January 1, 2022 |
2,723 |
330 |
619 |
86 |
112 |
3,870 |
Depreciation for the year |
763 |
90 |
218 |
83 |
128 |
1,282 |
Eliminated on disposal |
(27) |
(5) |
- |
- |
- |
(32) |
Impairment loss |
730 |
- |
- |
- |
- |
730 |
Reclassifications |
(222) |
- |
- |
222 |
- |
- |
Currency translation differences |
(67) |
- |
(9) |
(3) |
(7) |
(86) |
As at December 31, 2022 |
3,900 |
415 |
828 |
388 |
233 |
5,764 |
Depreciation for the year |
920 |
84 |
103 |
108 |
238 |
1,453 |
Eliminated on disposal |
(84) |
(33) |
(2) |
(8) |
- |
(127) |
Impairment loss |
34 |
21 |
6 |
23 |
- |
84 |
Reclassifications |
7 |
- |
(6) |
(1) |
- |
- |
Currency translation differences |
214 |
5 |
81 |
30 |
13 |
343 |
As at December 31, 2023 |
4,991 |
492 |
1,010 |
540 |
484 |
7,517 |
Net book value |
|
|
|
|
|
|
As at December 31, 2022 |
4,951 |
193 |
262 |
461 |
3,935 |
9,802 |
As at December 31, 2023 |
4,388 |
181 |
201 |
440 |
3,793 |
9,003 |
|
Land and buildings |
Motor vehicles |
Machinery and equipment |
Total |
Cost |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
As at January 1, 2022 |
8,913 |
611 |
341 |
9,865 |
Additions |
86 |
174 |
1,921 |
2,181 |
Disposals due to expiry of lease |
- |
(36) |
- |
(36) |
Disposals due to business combination* |
(467) |
- |
- |
(467) |
Modification to lease terms** |
(1,199) |
- |
- |
(1,199) |
Currency translation differences |
(381) |
(67) |
(26) |
(474) |
As at December 31, 2022 |
6,952 |
682 |
2,236 |
9,870 |
Additions |
99 |
140 |
858 |
1,096 |
Disposals due to expiry of lease |
(330) |
(28) |
(32) |
(390) |
Modification to lease terms *** |
(253) |
(110) |
- |
(362) |
Currency translation differences |
311 |
33 |
201 |
545 |
As at December 31, 2023 |
6,780 |
717 |
3,262 |
10,759 |
Depreciation |
|
|
|
|
As at January 1, 2022 |
1,716 |
109 |
66 |
1,891 |
Depreciation for the year |
730 |
140 |
68 |
938 |
Disposals due to expiry of lease |
- |
(36) |
- |
(36) |
Modification to lease terms** |
(693) |
- |
- |
(693) |
Currency translation differences |
(34) |
(6) |
(9) |
(49) |
As at December 31, 2022 |
1,719 |
207 |
125 |
2,051 |
Depreciation for the year |
703 |
157 |
145 |
1,005 |
Disposals due to expiry of lease |
(301) |
(25) |
(33) |
(359) |
Modification to lease terms*** |
(173) |
(41) |
- |
(214) |
Currency translation differences |
125 |
11 |
7 |
144 |
As at December 31, 2023 |
2,073 |
309 |
245 |
2,627 |
Net book value |
|
|
|
|
As at December 31, 2022 |
5,233 |
475 |
2,111 |
7,819 |
As at December 31, 2023 |
4,707 |
408 |
3,017 |
8,132 |
*With the acquisition of ChemTex Laboratories' property, plant and equipment, the Group no longer has a lease liability with a third party.
**The Group agreed to shorten the agreed lease terms of two existing leases from 2032 to 2027. These modifications have resulted in a reduction in the total amounts payable under the leases and a reduction to both of the right-of-use assets and lease liabilities with effect from the date of modification.
***The Group terminated certain lease agreements prior to their expiry resulting in the disposal of the right-of-use assets and related liabilities. The disposal resulted in a US$15,000 net gain.
|
|
As at |
|
As at |
|
|
December 31, 2023 |
|
December 31, 2022 |
Other non-current assets |
|
US$'000 |
|
US$'000 |
Deposits |
|
75 |
|
80 |
Other prepayments |
|
7 |
|
57 |
Other non-current assets |
|
82 |
|
137 |
|
|
As at |
|
As at |
|
|
December 31, 2023 |
|
December 31, 2022 |
Inventories |
|
US$'000 |
|
US$'000 |
Functional ingredients & materials |
|
9,154 |
|
11,420 |
Functional consumer goods |
|
2,096 |
|
1,748 |
Total inventories |
|
11,250 |
|
13,168 |
|
|
As at |
As at |
|
|
December 31, 2023 |
December 31, 2022 |
Trade receivables |
|
US$'000 |
US$'000 |
Not past due |
|
3,154 |
2,788 |
< 30 days |
|
1,269 |
520 |
31-60 days |
|
344 |
781 |
61-90 days |
|
549 |
215 |
91-120 days |
|
69 |
180 |
>120 days |
|
776 |
2,407 |
Total trade receivables |
|
6,161 |
6,891 |
Provision for expected credit losses |
|
(488) |
(404) |
Total trade receivables (net) |
|
5,673 |
6,487 |
|
|
As at |
|
As at |
|
|
December 31, 2023 |
|
December 31, 2022 |
Total other receivables and prepayments |
US$'000 |
|
US$'000 |
|
Contract assets |
|
34 |
|
115 |
Receivables from tax authorities |
|
2,092 |
|
1,864 |
Prepayments |
|
1,612 |
|
1,023 |
Other receivables |
|
611 |
|
1,260 |
Total other receivables and prepayments |
|
4,349 |
|
4,262 |
Amounts relating to contract assets are balances due from customers under construction contracts that arise when the Group receives payments from customers in line with a series of performance-related milestones. The Group recognizes a contract asset for any work performed. Any amount previously recognized as a contract asset is reclassified to trade receivables at the point at which it is invoiced to the customer.
|
As at December 31, 2023 |
As at December 31, 2022 |
Contract assets |
US$'000 |
US$'000 |
Research and development services |
34 |
65 |
Exclusivity services |
- |
50 |
Total contract assets |
34 |
115 |
Current assets |
34 |
115 |
Non-current assets |
- |
- |
Total contract assets |
34 |
115 |
Revenues related to research and development services were recognized at the point of delivering proof of concept and completing testing services. Performance obligations related to exclusivity services were deemed fulfilled by the Group upon completion of the contractual term. Payment for the above services is not due from the customer yet and therefore a contract asset is recognized.
The directors of the Company always measure the loss allowance on amounts due from customers at an amount equal to lifetime ECL, taking into account the historical default experience, the nature of the customer and where relevant, the sector in which they operate. There has been no change in the estimation techniques or significant assumptions made during the current reporting period in assessing the loss allowance for the amounts due from customers under construction contracts.
The following table details the risk profile of amounts due from customers based on the Group's provision matrix. Based on the historic default experience, the following expected credit loss has been recognized:
|
As at December 31, 2023 |
As at December 31, 2022 |
Expected credit loss |
US$'000 |
US$'000 |
Expected credit loss rate |
0% |
0% |
Estimated total gross carrying amount at default |
34 |
115 |
Lifetime ECL |
- |
- |
Net carrying amount |
34 |
115 |
Movements in the Company's share capital and share premium account were as follows:
|
|
Number of shares |
Share capital |
Share premium |
Totals |
|
|
No. |
US$'000 |
US$'000 |
US$'000 |
Balance as of January 1, 2022 |
|
130,583,536 |
51,523 |
144,191 |
195,714 |
Issue of shares to vendors of Life Materials |
|
347,552 |
141 |
471 |
612 |
Issue of shares as deferred consideration |
|
3,461,615 |
1,359 |
2,921 |
4,280 |
Issue of shares to Advisory Board and others |
|
164,721 |
60 |
175 |
235 |
Issue of shares to vendors of ChemTex Labs |
|
2,176,884 |
795 |
1,177 |
1,972 |
Issue of shares to vendors of Chrisal |
|
3,348,164 |
1,223 |
1,838 |
3,061 |
Balance as at December 31, 2022 |
|
140,082,472 |
55,101 |
150,773 |
205,874 |
Issue of shares Tarn Pure (a) |
|
455,435 |
160 |
212 |
372 |
Balance as at December 31, 2023 |
|
140,537,907 |
55,261 |
150,985 |
206,246 |
The par value of all shares is £0.30. All shares in issue were allotted, called up and fully paid.
The share premium account represents the amount received on the issue of ordinary shares by the Company in excess of their nominal value and is non-distributable.
The Company issued new ordinary shares for the following:
(a) On January 12, 2023, HeiQ plc completed the acquisition of 100% of the issued share capital and voting rights of Tarn Pure for a total consideration of US$1,237,000. The purchase consideration was payable partly by the issue of 455,435 new ordinary shares for (US$372,000). See Note 4 for details.
As of December 2023, 1,062,738 options vested with a strike price of £1.23. Following the vesting and employee departures, the number of options expected to vest dropped to 938,502 as per December 31, 2023 (June 30, 2023: 2,279,236; December 31, 2022: 2,497,281). The expense arising from these share-based payment transactions was US$49,000 for the six months ended December 31, 2023 and US$ 181,000 for the year ended December 31, 2023 which compares against an income of US$12,000 for the year ended December 31, 2022 following a drop in market expectations during the second half of 2022. In the six months ended June 30, 2022, the Group incurred an expense of US$415,000.
Details of the share options outstanding and exercisable during the year are as follows:
|
As at December 31, 2023 |
|
As at December 31, 2022 |
|||
|
Number of options |
Weighted average exercise price (£) |
|
Number of options |
Weighted average exercise price (£) |
|
Outstanding at beginning of year |
11,525,911 |
1.05 |
|
8,707,658 |
1.14 |
|
Granted during the year |
|
|
|
3,349,125 |
0.83 |
|
Forfeited during the year |
(2,289,440) |
1.06 |
|
(530,872) |
1.12 |
|
Lapsed during the year |
(3,842,184) |
1.23 |
|
- |
- |
|
Vesting during the year |
(1,062,738) |
1.23 |
|
- |
- |
|
Outstanding at the end of the year |
4,331,549 |
0.84 |
|
11,525,911 |
1.05 |
|
|
As at December 31, 2023 |
|
As at December 31, 2022 |
|||
|
Number of options |
Weighted average exercise price (£) |
|
Number of options |
Weighted average exercise price (£) |
|
Exercisable at beginning of year |
- |
- |
|
- |
- |
|
Vesting during the year |
1,062,738 |
1.23 |
|
- |
- |
|
Exercisable at the end of the year |
1,062,738 |
1.23 |
|
- |
- |
|
Remuneration of US$764,000 in relation to the acquisition of Life Materials Technologies Limited is linked to a service period of five years. An expense of US$78,000 was recognized in the six months ended December 31, 2023 (year ended December 31, 2023: US$153,000; year ended December 31, 2022: US$150,000). The remainder of US$382,000 is expected to be expensed over the period from January 1, 2024, to June 30, 2026.
Other reserves comprise the share-based payment reserve, the merger reserve, the currency translation reserve and the other reserve.
The retained deficit comprises all other net gains and losses and transactions with owners not recognized elsewhere.
Movements in the other reserves were as follows:
|
|
Share- based payment reserve |
Merger reserve |
Currency translation reserve |
Other reserve |
Total Other reserves |
|
|
Note |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
|
Balance at January 1, 2022 |
|
474 |
(126,912) |
387 |
(1,144) |
(127,195) |
|
Other comprehensive (loss)/income |
|
- |
- |
(1,914) |
1,104 |
(810) |
|
Total comprehensive (loss)/income for the year |
|
- |
- |
(1,914) |
1,104 |
(810) |
|
Share-based payment charges |
25 |
(12) |
- |
- |
- |
(12) |
|
Transactions with owners |
|
(12) |
- |
- |
- |
(12) |
|
Balance at December 31, 2022 |
|
462 |
(126,912) |
(1,527) |
(40) |
(128,017) |
|
Other comprehensive (loss)/income |
|
- |
- |
975 |
31 |
1,006 |
|
Total comprehensive (loss)/income for the period |
|
- |
- |
975 |
31 |
1,006 |
|
Share-based payment charges |
25 |
181 |
- |
- |
- |
181 |
|
Transactions with owners |
|
181 |
- |
- |
- |
181 |
|
Balance at December 31, 2023 |
|
643 |
(126,912) |
(552) |
(9) |
(126,830) |
|
The share-based payment reserve arises from the requirement to fair value the issue of share options at grant date. Further details of share options are included at Note 25.
The currency translation reserve represents cumulative foreign exchange differences arising from the translation of the financial statements of foreign subsidiaries and is not distributable by way of dividends.
In October 2023, HeiQ Chrisal N.V. declared and paid a dividend of US$42,000 of which 29% or US$12,000 was paid to minority shareholders.
Future minimum lease payments associated with leases were as follows:
|
As at |
As at |
Lease payments |
US$'000 |
US$'000 |
Not later than one year |
1,211 |
1,301 |
Later than one year and not later than five years |
3,665 |
3,813 |
Later than five years |
3,542 |
3,387 |
Total minimum lease payments |
8,419 |
8,501 |
Less: Future finance charges |
(615) |
(679) |
Present value of minimum lease payments |
7,805 |
7,822 |
|
|
|
Later than one year and not later than five years |
1,128 |
1,264 |
Later than five years |
6,677 |
6,558 |
Total minimum lease payments |
7,805 |
7,822 |
In February 2023, nine employees were made redundant which resulted in a curtailment gain US$141,000. The valuation was based on the participants data as of year-end 2022 and the valuation assumptions as of end of February 2023.
In October 2023, the Board of Trustees of the AXA pension fund decided that a new enveloping conversion rate of 5.20% will apply to retirements from 1 January 2025 for men and women aged 65. For retirements up to the end of 2024, the split conversion rates of 6.80% for mandatory savings capital and 5.00% for men aged 65 and 4.88% for women aged 64 for supplementary savings capital will continue to apply. The decision was accounted for as a plan amendment at the time the decision was made. The valuation was based on the participants data as at December 31, 2023 and the valuation assumptions as at October 31, 2023. The impact was recognized as a plan amendment and a gain of US$341,000.
The components of the net defined benefits obligations included in non-current liabilities are as follows:
|
|
As at |
|
As at |
|
|
December 31, |
|
December 31, |
|
|
2023 |
|
2022 |
|
|
US$'000 |
|
US$'000 |
Fair value of plan assets |
|
8,126 |
|
9,616 |
Defined benefit obligations |
|
(9,032) |
|
(10,568) |
Funded status (net liability) |
|
(906) |
|
(952) |
|
|
|
|
|
Duration (years) |
|
14.6 |
|
13.8 |
Expected benefits payable in following year |
|
(352) |
|
(389) |
|
|
|
|
|
|
|
Year ended |
|
Year ended |
|
|
December 31, |
|
December 31, |
|
|
2023 |
|
2022 |
Development of obligations and assets |
|
US$'000 |
|
US$'000 |
Present value of funded obligations, beginning of year |
|
(10,568) |
|
(13,003) |
Employer service cost |
|
(417) |
|
(571) |
Employee contributions |
|
(321) |
|
(352) |
Past service gain |
|
341 |
|
- |
Curtailments/Settlements |
|
141 |
|
- |
Interest cost |
|
(236) |
|
(45) |
Benefits paid/(refunded) |
|
3,405 |
|
522 |
Actuarial (loss)/gain on benefit obligation |
|
(448) |
|
2,562 |
Currency (loss)/gain |
|
(937) |
|
319 |
Present value of funded obligations, end of year |
|
(9,032) |
|
(10,568) |
|
|
|
|
|
Defined benefit obligation participants |
|
(7,757) |
|
(10,568) |
Defined benefit obligation pensioners |
|
(1,274) |
|
- |
Present value of funded obligations, end of year |
|
(9,032) |
|
(10,568) |
|
|
|
|
|
|
|
|
|
|
Fair value of plan assets, beginning of year |
|
9,616 |
|
10,858 |
Expected return on plan assets |
|
215 |
|
37 |
Employer's contributions |
|
320 |
|
352 |
Employees' contributions |
|
321 |
|
352 |
Benefits (paid)/refunded |
|
(3,405) |
|
(522) |
Admin expense |
|
(19) |
|
(21) |
Actuarial (loss)/gain on plan assets |
|
130 |
|
(1,182) |
Currency gain/(loss) |
|
850 |
|
(258) |
Fair value of plan assets, end of year |
|
8,126 |
|
9,616 |
|
|
|
|
|
Movements in net liability recognized in statement of financial position:
|
Year ended |
|
Year ended |
|
December 31, |
|
December 31, |
|
2023 US$'000 |
|
2022 US$'000 |
Net liability, beginning of year |
(952) |
|
(2,146) |
Employer service cost |
(417) |
|
(571) |
Interest cost |
(236) |
|
(45) |
Expected return on plan assets |
215 |
|
37 |
Admin expense |
(19) |
|
(21) |
Past service cost recognized in year |
341 |
|
- |
Curtailment, settlement, plan amendment gain (loss) |
148 |
|
- |
Employer's contributions (following year expected contributions) |
320 |
|
352 |
Prepaid (accrued) pension cost: |
(352) |
|
247 |
- operating income (expense) |
373 |
|
(240) |
- finance expense |
(22) |
|
(7) |
Total gains recognized within other comprehensive income |
(218) |
|
1,380 |
Currency loss |
(87) |
|
62 |
Net liability, end of year |
(906) |
|
(952) |
|
|
|
|
Expected employer's cash contributions for following year |
269 |
|
360 |
|
|
|
|
The assets of the scheme are invested on a collective basis with other employers. The allocation of the pooled assets between asset categories is as follows:
|
|
As at December 31, |
|
As at December 31, |
|
|
2023 |
|
2022 |
|
|
US$'000 |
|
US$'000 |
Cash |
|
3.1% |
|
2.8% |
Bonds |
|
29.6% |
|
29.1% |
Equities |
|
33.6% |
|
33.2% |
Property (incl. mortgages) |
|
28.9% |
|
31.3% |
Other |
|
4.8% |
|
3.6% |
Total |
|
100.0% |
|
100.0% |
|
|
|
|
|
|
Year ended |
|
Year ended |
|
December 31, |
|
December 31, |
|
2023 US$'000 |
|
2022 US$'000 |
Employer service cost |
417 |
|
(571) |
Past service cost recognized in year |
341 |
|
- |
Interest cost |
(236) |
|
(45) |
Expected return on plan assets |
215 |
|
37 |
Admin expense |
(19) |
|
(21) |
Curtailment, settlement, plan amendment gain (loss) |
148 |
|
- |
Components of defined benefit costs recognized in profit or loss |
32 |
|
(600) |
|
Year ended |
|
Year ended |
|
December 31, |
|
December 31, |
|
2023 |
|
2022 |
|
US$'000 |
|
US$'000 |
Actuarial gains/(losses) arising from plan experience |
314 |
|
193 |
Actuarial (losses)/gains arising from demographic assumptions |
- |
|
(23) |
Actuarial gains / (losses) arising from financial assumptions |
(762) |
|
2,392 |
Re-measurement of defined benefit obligations |
(448) |
|
2,562 |
Re-measurement of assets |
230 |
|
(1,182) |
Deferred tax asset recognized |
44 |
|
(276) |
Other |
- |
|
- |
Total recognized in OCI |
(174) |
|
1,104 |
The principal assumptions used in determining pension and post-employment benefit obligations for the plan are shown below:
|
|
As at |
|
As at |
|
|
December 31, |
|
December 31, |
|
|
2023 |
|
2022 |
|
|
US$'000 |
|
US$'000 |
Discount rate |
|
1.50% |
|
2.25% |
Interest credit rate |
|
2.00% |
|
2.25% |
Average future salary increases |
|
2.00% |
|
2.50% |
Future pension increases |
|
0.00% |
|
0.00% |
Mortality tables used |
|
BVG 2020 GT |
|
BVG 2020 GT |
Average retirement age |
|
65/65 |
|
65/65 |
The forecasted contributions of the Group for the 2024 calendar year amount to US$269,000.
A quantitative sensitivity analysis for significant assumptions is as follows:
|
|
As at |
As at |
|
|
December 31, |
December 31, |
|
|
2023 |
2022 |
Impact on defined benefit obligation |
|
US$'000 |
US$'000 |
Discount rate + 0.25% |
|
(320) |
(346) |
Discount rate - 0.25% |
|
339 |
368 |
Salary increase + 0.25% |
|
41 |
47 |
Salary increase - 0.25% |
|
(40) |
(46) |
Pension increase + 0.25% |
|
183 |
179 |
Pension decrease - 0.25% (not lower than 0%) |
|
- |
- |
A negative value corresponds to a reduction of the defined benefit obligation, a positive value to an increase of the defined benefit obligation.
The sensitivity analyses above have been determined based on a method that extrapolates the impact on the defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period. The sensitivity analyses are based on a change in a significant assumption, keeping all other assumptions constant. The sensitivity analyses may not be representative of an actual change in the defined benefit obligation as it is unlikely that changes in assumptions would occur in isolation from one another.
Life Materials Technologies Limited, Thailand, also has a pension scheme which gives rise to defined benefit obligations under IAS 19. The pension expense in profit and loss was US$10,000 (2022: US$1,000) which results in a US$144,000 net defined liability as at December 31, 2023 (2022: US$134,000).
The Group's borrowings are held at amortized cost. They consist of the following:
|
As at |
As at |
Borrowings |
US$'000 |
US$'000 |
Unsecured bank loans |
10,112 |
3,573 |
Secured bank loans |
304 |
628 |
Loans from related parties |
1,494 |
- |
Loans from non-controlling interest |
- |
137 |
Total borrowings |
11,910 |
4,338 |
The following table provides a reconciliation of the Group's future maturities of its total borrowings for each year presented:
|
As at |
As at |
Maturity of borrowings |
US$'000 |
US$'000 |
Not later than one year |
10,409 |
2,893 |
Later than one year but less than five years |
1,010 |
1,029 |
After more than five years |
491 |
416 |
Total borrowings |
11,910 |
4,338 |
The other principal features of the Group's borrowings are as follows:
|
|
|
As at December 31, 2023 |
|
As at December 31, 2022 |
|||
Description |
Currency |
Repayment date |
Principal US$'000 |
Interest rate |
|
Principal US$'000 |
Interest rate |
|
Credit facility |
CHF |
February 2024 |
6,461 |
4.67% |
|
2,574 |
2.20% |
|
Credit facility |
CHF |
June 2024 |
1,175 |
5.45% |
|
- |
- |
|
Credit facility |
CHF |
September 2024 |
940 |
4.70% |
|
- |
- |
|
Various bank loans1) |
EUR |
1-10 years |
1,504 |
2.93% |
|
999 |
2.21% |
|
Bank loan |
GBP |
April 2026 |
32 |
2.50% |
|
- |
- |
|
Outstanding at the end of the year |
|
|
10,112 |
|
|
3,573 |
|
|
1) Several loans repayable over ten years. The loans are repayable over a period of up to ten 10 years. These loans have fixed interest rates between 1.19% and 4.50% and the weighted average fixed interest rate on the outstanding balances is 2.93%.
The Group took out a bank loan in October 2020 which incurs interest at a fixed rate of 3.25%. The loan is secured by property owned by a company which is controlled by a minority shareholder of HeiQ Medica. As at December 31, 2023, US$304,000 is outstanding (December 31, 2022: US$628,000).
In December 2023, Cortegrande AG, a company controlled by Carlo Centonze, granted a loan to HeiQ Group in the amount of EUR 1,350,000 (approximately US$1,494,000). The loan was increased to EUR 1,475,000 in January 2024. In March 2024, most of the outstanding loan was repaid in shares as part of the settlement of the convertible loan note issued by the Company. As of March 28, 2024, the remaining loan amounts to EUR 400,000, incurs interest at 4.5% and is repayable in June 2024.
A loan disclosed in the 2022 annual report in the amount of BRL 715,683 (US$137,000) which was payable to a minority shareholder of Life Materials Latam Ltda, Brazil is no longer consolidated following the deconsolidation of the subsidiary.
The following are the major deferred tax liabilities and assets recognized by the Group and movements thereon during the current and prior reporting period.
|
Pension fund obligations |
Tax losses |
Share-based payments |
Capital allowances, depreciation and other temporary differences |
Total |
Deferred tax |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
Balance at January 1, 2022 |
429 |
178 |
85 |
(1,686) |
(994) |
Charge to profit or loss |
49 |
(150) |
1 |
681 |
581 |
Charge to other comprehensive income |
(276) |
- |
- |
- |
(276) |
Foreign currency differences |
(12) |
(28) |
5 |
9 |
(26) |
Balance as at December 31, 2022 |
190 |
- |
91 |
(996) |
(715) |
Charge to profit or loss |
(453) |
- |
(86) |
121 |
(417) |
Charge to other comprehensive income |
249 |
- |
|
|
249 |
Arising from business combinations |
- |
- |
- |
(201) |
(201) |
Foreign currency differences |
14 |
- |
(5) |
4 |
13 |
Balance as at December 31, 2023 |
- |
- |
- |
(1,072) |
(1,072) |
Deferred tax assets related to pension fund obligations and share-based payments were derecognized due to the current operational results and the uncertainty about future profits in the Swiss tax jurist. Deferred tax liabilities related to capital allowances and depreciation increased following the recognition of intangible assets acquired in the Tarn Pure acquisition.
Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis. The following is the analysis of the deferred tax balances (after offset) for financial reporting purposes:
|
|
As at |
|
As at |
Deferred tax |
|
US$'000 |
|
US$'000 |
Deferred tax assets |
|
312 |
|
538 |
Deferred tax liabilities |
|
(1,384) |
|
(1,253) |
Net deferred tax assets (liabilities) |
|
(1,072) |
|
(715) |
Other non-current liabilities |
As at December 31, 2023 US$'000 |
As at US$'000 |
Defined benefit obligation IAS 19 Switzerland |
906 |
952 |
Defined benefit obligation IAS 19 Thailand |
144 |
134 |
Contract liabilities |
3,932 |
3,614 |
Deferred consideration Tarn Pure acquisition |
19 |
- |
Deferred grant income |
9 |
14 |
Total other non-current liabilities |
5,010 |
4,714 |
|
As at December 31, 2023 |
As at December 31, 2022 |
Trade and other payables |
US$'000 |
US$'000 |
Trade payables |
4,446 |
3,321 |
Payables to tax authorities |
462 |
375 |
Other payables |
1,764 |
1,626 |
Total trade and other payables |
6,672 |
5,322 |
Trade payables principally comprise amounts outstanding for trade purchases and ongoing costs. Other payables relate to employee-related expenses, utilities and other overhead costs. Typically, no interest is charged on the trade payables. The Group has financial risk management policies in place to ensure that all payables are paid within the pre-agreed credit terms.
The directors consider that the carrying amount of trade payables approximates to their fair value.
|
As at December 31, 2023 |
As at December 31, 2022 |
Accrued liabilities |
US$'000 |
US$'000 |
Costs of goods sold |
967 |
875 |
Personnel expenses |
1,338 |
1,737 |
Other operating expenses |
2,178 |
2,366 |
Total accrued liabilities |
4,483 |
4,978 |
|
As at December 31, 2023 |
As at December 31, 2022 |
Deferred revenue |
US$'000 |
US$'000
|
Contract liabilities |
1,380 |
1,176 |
Prepayments for unshipped goods |
22 |
94 |
Deferred grant income |
21 |
15 |
Total deferred revenue |
1,423 |
1,285 |
|
As at December 31, 2023 |
As at December 31, 2022 |
Contract liabilities |
US$'000 |
US$'000 |
Exclusivity agreements |
2,812 |
1,832 |
Research and development services |
2,500 |
2,958 |
Total contract liabilities |
5,312 |
4,790 |
Current liabilities (Note 34) |
1,380 |
1,176 |
Non-current liabilities (Note 31) |
3,932 |
3,614 |
Total contract liabilities |
5,312 |
4,790 |
Revenue relating to both exclusivity and research and development services is recognized over time although the customer pays up-front in full for these services. A contract liability is recognized for revenue relating to the services at the time of the initial sales transaction and is released over the service period.
|
As at December 31, 2023 |
As at December 31, 2022 |
Other current liabilities |
US$'000 |
US$'000 |
Deferred consideration in relation to acquisitions |
208 |
92 |
Call option liability |
- |
686 |
Other current liabilities |
208 |
778 |
The deferred consideration in relation to business acquisition and related financing expense are summarized below:
Deferred consideration in relation to acquisitions |
Chemtex |
RAS |
Life |
Tarn Pure |
Total |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
US$'000 |
|
As at December 31, 2021 |
279 |
3,152 |
2,652 |
- |
6,083 |
Foreign exchange revaluation |
- |
(276) |
- |
- |
(276) |
Consideration settled in cash |
(187) |
- |
(1,400) |
- |
(1,587) |
Consideration settled in shares |
- |
(2,875) |
(1,252) |
- |
(4,127) |
As at December 31, 2022 |
92 |
- |
- |
- |
92 |
Additions from Tarn Pure acquisition as per Note 4a |
- |
- |
- |
244 |
244 |
Consideration settled in cash |
- |
- |
- |
(110) |
(110) |
Amortization of fair value discount |
- |
- |
- |
1 |
1 |
As at December 31, 2022 |
92 |
- |
- |
135 |
227 |
|
As at December 31, 2023 |
As at December 31, 2022 |
Deferred consideration |
US$'000 |
US$'000 |
Current liabilities |
208 |
92 |
Non-current liabilities |
19 |
- |
Total deferred consideration |
227 |
92 |
A minority shareholder of one of the Group's subsidiaries has made a claim in court regarding the interpretation of certain put-option rights on shares of the same subsidiary. The Company considers these option rights as lapsed as per the Shareholder Agreement. At present, it is not possible to determine the outcome of these matters. Hence, no provision has been made in the financial statements for their ultimate resolution.
Provisions |
|
As at December 31, 2023 US$'000 |
As at December 31, 2022 US$'000 |
|
Current liabilities |
|
- |
339 |
|
Non-current liabilities |
|
- |
- |
|
Total provisions |
|
- |
339 |
|
|
|
|
||
|
|
|
||
|
Legal/Compliance provision |
Total |
||
Provisions |
US$'000 |
US$'000 |
||
Balance at January 1, 2022 |
- |
- |
||
Additional provision in the year |
339 |
339 |
||
Utilization of provision |
- |
- |
||
Exchange difference |
- |
- |
||
Balance as at December 31, 2022 |
339 |
339 |
||
Additional provision in the period |
|
|
||
Utilization of provision |
(339) |
(339) |
||
Exchange difference |
|
|
||
Balance as at December 31, 2023 |
- |
- |
||
Certain shares were issued during the year for a non-cash consideration as described in Note 24.
During the year ended December 31, 2022, additions to buildings and land amounting to US$1,862,000 million were financed by issuing shares.
The Company defines working capital as trade receivables, other receivables and prepayments less trade and other payables, accrued liabilities and deferred revenue.
Year ended December 31, 2023 |
Opening balances |
Assumed on acquisition of assets |
Disposal of subsidiary |
Change in balance |
Closing balances |
|
US$'000 |
US$'000 |
|
US$'000 |
US$'000 |
||
Inventories |
|
13,168 |
13 |
(5) |
(1,926) |
11,250 |
Trade receivables |
|
6,487 |
2 |
- |
(816) |
5,673 |
Other receivables and prepayments |
|
4,262 |
10 |
(6) |
83 |
4,349 |
Trade and other receivables and prepayments |
10,749 |
12 |
(6) |
(733) |
10,022 |
|
Trade and other payables |
|
5,322 |
2 |
(16) |
1,364 |
6,672 |
Accrued liabilities |
|
4,978 |
- |
- |
(495) |
4,483 |
Deferred revenue incl. non-current contract liabilities |
|
4,913 |
- |
- |
451 |
5,364 |
Trade and other payables, accrued liabilities and deferred revenue |
15,213 |
2 |
(16) |
1,320 |
16,519 |
Year ended December 31, 2022 |
Opening balances |
Assumed on acquisition of assets |
Change in balance |
Closing balances |
|
US$'000 |
US$'000 |
US$'000 |
US$'000 |
||
Inventories |
|
13,770 |
- |
(602) |
13,168 |
Trade receivables |
|
14,656 |
- |
(8,169) |
6,487 |
Other receivables and prepayments |
|
3,876 |
- |
386 |
4,262 |
Trade and other receivables and prepayments |
18,532 |
- |
(7,783) |
10,749 |
|
Trade and other payables |
|
8,271 |
- |
(2,949) |
5,322 |
Accrued liabilities |
|
3,386 |
9 |
1,583 |
4,978 |
Deferred revenue incl. non-current contract liabilities |
|
1,004 |
- |
3,909 |
4,913 |
Trade and other payables, accrued liabilities and deferred revenue |
12,661 |
9 |
2,543 |
15,213 |
Year ended December 31, 2023 |
|
US$'000 |
Consideration payment for acquisition of Tarn Pure |
|
730 |
Cash assumed on acquisition of Tarn Pure |
|
(12) |
Net consideration payment for acquisitions of businesses |
|
718 |
Year ended December 31, 2022 |
|
US$'000 |
Consideration payment for acquisition of Life Materials Technologies Ltd |
|
1,400 |
Consideration payment for acquisition of ChemTex assets |
|
187 |
Net consideration payment for acquisitions of businesses and assets |
|
1,587 |
ECSA, a company controlled by a director of HeiQ Materials AG supplied materials and services totalling US$36,000 to
HeiQ Materials AG, in the year ended December 31, 2023 (2022: US$88,000). The transactions were made on terms equivalent to those in arm's length transactions.
The directors have deferred payment of their board fees earned in the period July - December 2023 and thus the Company has recorded a corresponding liability against each of the directors.
|
As at December 31, 2023 |
As at December 31, 2022 |
Loans due to related parties |
US$'000 |
US$'000 |
Cortegrande AG, €1,350,000 |
1,494 |
- |
Loans due to related parties |
1,494 |
- |
The associates have provided the Group with short-term loans at rates comparable to the average commercial rate of interest.
In February 2024 the Group completed the acquisition of two industrial properties in Portugal for a total consideration of EUR5.0 million (including taxes). In March 2024, the Group was able to refinance the acquisition of the smaller property with a mortgage amounting to EUR 750,000. The refinancing of the larger property is still ongoing as of March 28, 2024.
In March 2024, the Group issued 28,000,000 new ordinary shares raising in aggregate £2.44 million (gross). Following the issue and allotment of the New Ordinary Shares the Company has 168,537,907 Ordinary Shares in issue. The Company holds no Ordinary Shares in treasury, and therefore the total number of voting rights in the Company is 168,537,907. All new shares have been issued at £0.087 per share.
Directors have participated in the fundraise and acquired Convertible Loan Note shares as follows:
Director name |
Number of ordinary shares acquired |
Carlo Centonze (via Cortegrande AG) |
8,808,793 |
Esther Dale |
180,974 |
Xaver Hangartner |
73,368 |
Furthermore, the Group subdivided each existing ordinary share of 30p into one new ordinary share of 5 pence and one deferred share of 25 pence.
In March 2024, Robert van de Kerkhof. who was appointed Director in November 2023, was nominated as the new Chairman replacing Esther Dale Kolb who resigned from her role as Chair and Director as of March 31, 2024.
As at December 31, 2023, the Company did not have any single identifiable controlling party.